MacroGenics updates pipeline progress in third-quarter 2026 report
The company completed Phase 1 dose escalation for MGC028 and dosed its first patient with MGC030, while cash climbed to $287.7 million.
SEC filing
5 stories
The company completed Phase 1 dose escalation for MGC028 and dosed its first patient with MGC030, while cash climbed to $287.7 million.
SEC filing
Emil Kuriakose and Michael Vasconcelles join as independent directors effective October 30, 2026, expanding the board to eleven members.
SEC filing
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)
The October 20, 2026 deal gives Imunon equity, milestone payments up to $16.5 million, and royalties, while it keeps focus on its Phase 3 OVATION 3 trial.
SEC filing (5)